SCHEMBL6501138

SCHEMBL6501138

Cc1nc(CCOc2ccc(NC(=O)c3cc(C(F)(F)F)c(C)cc3-c3ccccc3)cc2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 2/20 0.41
STAT1 P42224 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
S1PR1 P21453 4/20 0.40
S1PR3 Q99500 3/20 0.40
POLB P06746 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TP53 P04637 2/20 0.39
DGAT1 O75907 1/20 0.39
GRM5 P41594 1/20 0.39
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
LMNA P02545 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680191 0.88 LMNA (0.38) MAPTHTTNPC1RAB9AKDM4E
SCHEMBL6677053 0.85 ITGB1 (0.44) MAPTGAAS1PR1S1PR3POLB
SCHEMBL6799168 0.82 TP53 (0.49) MAPTGAANPC1STAT1RAB9A
SCHEMBL6489479 0.81 TP53 (0.47) MAPTNPC1RAB9AKDM4EPOLB
SCHEMBL6488813 0.80 MAPT (0.47) MAPTGAAHTTNPC1RAB9A
SCHEMBL6499318 0.79 MAPT (0.49) MAPTGAAHTTNPC1STAT1
SCHEMBL7079416 0.78 MAPT (0.44) MAPTGAAHTTKDM4EPOLB
SCHEMBL6497776 0.76 GCGR (0.49) MAPTNPC1RAB9AKDM4ERXFP1
SCHEMBL6489237 0.76 MAPT (0.46) MAPTNPC1STAT1RAB9AKDM4E
SCHEMBL6678296 0.76 POLB (0.46) MAPTGAAS1PR1S1PR3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885GAA 2041/4885HTT 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.